The low levels of ADO production by melanoma cells observed after providing NAD+ as substrate may indicate that enzymatic function either of CD38 or CD203a/PC-1, which converts ADPR produced from NAD+ by CD38 to AMP, is inefficient. Here, CD38 is linked to melanoma.